A Study of JADE101 in Participants With Immunoglobulin A Nephropathy (NCT07541287)
A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)
🩺 Plain-English Summary (8th-Grade Level)
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.
Who can join: Review the eligibility criteria below.
Location: Jade Clinical Site — Chula Vista, California
Age range: 18 Years to 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Jade Clinical Site — Chula Vista, California
- Jade Clinical Site — Arvada, Colorado
- Jade Clinical Site — Denver, Colorado
- Jade Clinical Site — Orlando, Florida
- Jade Clinical Site — Pembroke Pines, Florida
- Jade Clinical Site — Houston, Texas
- Jade Clinical Site — Concord, New South Wales
- Jade Clinical Site — Christchurch,
- Jade Clinical Site — Anyang-si,
- Jade Clinical Site — Seongnam-si,
- Jade Clinical Site — Seoul,
- Jade Clinical Site — Seoul,
- Jade Clinical Site — Seoul,
- Jade Clinical Site — Suwon,
- Jade Clinical Site — Taipei,
📞 Contact the Study Coordinator
Phone: (781) 201-4703
Email: JADE101clinicaltrials@jadebiosciences.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in IgA Nephropathy
- A Study of Zigakibart in Adults With IgA Nephropathy — Birmingham, Alabama
- Atrasentan in Patients With IgA Nephropathy — Birmingham, Alabama
- Atrasentan in Patients With Proteinuric Glomerular Diseases — Glendale, California
- Atacicept in Subjects With IgA Nephropathy — Brisbane, California
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G — Lawrenceville, Georgia
- Study of BHV-1400 in IgA Nephropathy — Farmington, Connecticut
Explore by condition: All IgA Nephropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.